Nuclea Biotechnologies Partners with IBL-America
News Feb 25, 2014
Nuclea Biotechnologies, Inc. has recently announced that Immuno-Biological Laboratories Inc., (IBL-America) would be their primary US distributor for the serum HER-2/neu kits.
IBL-America, based in Minneapolis, MN, is a distributor of high quality diagnostic assays in various areas including autoimmunity, endocrinology, infectious disease, oncology, and neuroscience and offers technical laboratory services as well.
Nuclea is a specialist in serum based oncoprotein diagnostics and offers tests for In Vitro Diagnostic (IVD) and Research Use Only (RUO). Nuclea provides the only FDA-cleared through 510(k) IVD ELISA test for the measurement of serum HER-2/neu in the management and monitoring of women with metastatic breast cancer.
This microtiter based test enables laboratories to measure the level of HER-2/neu in serum in a cost-efficient and validated manner. This test is reimbursed by insurance companies and has a unique CPT code 83950.
Additionally, the two companies will coordinate joint marketing efforts for the serum HER-2/neu kits.
“As we continue to see the market respond to our serum HER-2/neu test, we’ve been securing partners who have strong distribution channels,” said Patrick Muraca, President and CEO of Nuclea. “IBL-America has a proven track record and I’m excited to have them as a partner.”
Mark Kowal, President and CEO of IBL-America stated “We, at IBL-America, are excited about the opportunity to work with the professionals at Nuclea. The HER-2/neu test is an excellent addition to our line of oncology products and we welcome this promising joint venture.”
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE